@article{a4403587e786432eb2752bdcee7d66e7,
title = "Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation",
keywords = "chondrocytes, cryopyrin-associated periodic syndromes, interleukin 1 receptor antagonist protein",
author = "Takehiko Mori and Masuho Saburi and Maki Hagihara and Masaaki Mori and Rie Yamazaki and Jun Kato",
note = "Funding Information: Competing interests TM received research funding from MSD KK, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi, Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; MM received research funding from Chugai Pharmaceutical, UCB Japan, CSL Behring, Abbvie Japan, Japan Blood Products Organization, Ayumi Pharmaceutical, Nippon Kayaku and Asahi Kasei, personal fees from MSD KK, and consulting fees from Daiichi Sankyo, and Taisho Pharmaceutical.",
year = "2021",
month = apr,
day = "1",
doi = "10.1136/annrheumdis-2020-218695",
language = "English",
volume = "80",
pages = "542--543",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "4",
}